{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:55:31Z","timestamp":1772117731235,"version":"3.50.1"},"reference-count":76,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010292","type":"journal-article","created":{"date-parts":[[2013,1,29]],"date-time":"2013-01-29T08:16:19Z","timestamp":1359447379000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome"],"prefix":"10.1002","author":[{"given":"Winfried","family":"H\u00e4user","sequence":"first","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen; Department of Psychosomatic Medicine and Psychotherapy; Langerstr. 3 M\u00fcnchen Germany D-81675"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Urr\u00fatia","sequence":"additional","affiliation":[{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Spain; Iberoamerican Cochrane Centre - IIB Sant Pau; c\/ Sant Antoni Maria Claret 171 Barcelona Spain 08041"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sera","family":"Tort","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Research (IIB Sant Pau); Iberoamerican Cochrane Centre; Sant Antoni Maria Claret 171 Edifici Casa de Convalesc\u00e8ncia Barcelona Catalonia Spain 08041"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurcan","family":"\u00dc\u00e7eyler","sequence":"additional","affiliation":[{"name":"University of W\u00fcrzburg; Department of Neurology; W\u00fcrzburg Germany 97080"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Walitt","sequence":"additional","affiliation":[{"name":"Washington Hospital Center; Georgetown University Medical Center; 110 Irving Street, NW Washington DC USA 20010"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,31]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD010292-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1002\/art.20485","article-title":"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder","volume":"50","author":"Arnold","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"1-3","key":"10.1002\/14651858.CD010292-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pain.2005.06.031","article-title":"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder","volume":"119","author":"Arnold","year":"2005","journal-title":"Pain"},{"issue":"12","key":"10.1002\/14651858.CD010292-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.3899\/jrheum.100365","article-title":"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Arnold","year":"2010","journal-title":"Journal of Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD010292-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1002\/art.27559","article-title":"Efficacy and safety of milnacipran 100 mg\/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Arnold","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD010292-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3899\/jrheum.090884","article-title":"A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia","volume":"37","author":"Branco","year":"2010","journal-title":"Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD010292-BIB0006|cit6","first-page":"91","article-title":"A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia","volume":"30","author":"Chappell","year":"2009","journal-title":"International Journal of General Medicine"},{"issue":"11","key":"10.1002\/14651858.CD010292-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.clinthera.2008.11.009","article-title":"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial","volume":"30","author":"Clauw","year":"2008","journal-title":"Clinical Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD010292-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3899\/jrheum.080734","article-title":"The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial","volume":"36","author":"Mease","year":"2009","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD010292-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.pain.2008.02.024","article-title":"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial","volume":"136","author":"Russell","year":"2008","journal-title":"Pain"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010292-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/hup.622","article-title":"A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia","volume":"19","author":"Vitton","year":"2004","journal-title":"Human Psychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD010292-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3899\/jrheum.101025","article-title":"Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study","volume":"38","author":"Branco","year":"2011","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD010292-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/AJP.0b013e31819be587","article-title":"A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia","volume":"25","author":"Chappell","year":"2009","journal-title":"Clinical Journal of Pain"},{"issue":"1","key":"10.1002\/14651858.CD010292-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0033-3182(98)71375-1","article-title":"An open clinical trial of venlafaxine treatment of fibromyalgia","volume":"39","author":"Dwight","year":"1998","journal-title":"Psychosomatics"},{"issue":"10","key":"10.1002\/14651858.CD010292-BIB0014|cit14","first-page":"1975","article-title":"Efficacy of milnacipran in patients with fibromyalgia","volume":"32","author":"Gendreau","year":"2005","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD010292-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1526-4637.2009.00755.x","article-title":"Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study","volume":"11","author":"Goldenberg","year":"2010","journal-title":"Pain Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010292-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4088\/PCC.v09n0511g","article-title":"Effective treatment of fibromyalgia comorbid with premenstrual dysphoric disorder with a low dose of venlafaxine","volume":"9","author":"Hsiao","year":"2007","journal-title":"Primary Care Companion to the Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD010292-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.semarthrit.2008.11.001","article-title":"Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia","volume":"39","author":"Mease","year":"2010","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD010292-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1185\/03007995.2012.677418","article-title":"Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia","volume":"28","author":"Saxe","year":"2012","journal-title":"Current Medical Research and Opinion"},{"issue":"11","key":"10.1002\/14651858.CD010292-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1345\/aph.1D112","article-title":"Venlafaxine treatment of fibromyalgia","volume":"37","author":"Sayar","year":"2003","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD010292-BIB0020|cit20","unstructured":"Wyeth Progress report: a multicenter, randomized, double-blind, placebo-controlled,parallel-group, adaptive-design, efficacy, safety and tolerability study of 4 fixed oral doses of DVSSR in adult outpatients with fibromyalgia syndrome Available at http:\/\/www.clinicalstudyresults.org\/documents\/company-study_9484_0.pdf"},{"key":"10.1002\/14651858.CD010292-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326(7382)","author":"Altman","year":"2003","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD010292-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4088\/PCC.08m00680","article-title":"Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials","volume":"11","author":"Arnold","year":"2009","journal-title":"Primary Care Companion to the Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010292-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"issue":"6","key":"10.1002\/14651858.CD010292-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3899\/jrheum.081090","article-title":"Minimal clinically important difference in the fibromyalgia impact questionnaire","volume":"36","author":"Bennett","year":"2009","journal-title":"Journal of Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD010292-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3899\/jrheum.100104","article-title":"Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome - a systematic review and metaanalysis of randomized controlled trials","volume":"37","author":"Bernardy","year":"2010","journal-title":"Journal of Rheumatology"},{"issue":"12 Suppl","key":"10.1002\/14651858.CD010292-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjmed.2009.09.008","article-title":"Pathophysiology of fibromyalgia","volume":"122","author":"Bradley","year":"2009","journal-title":"American Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD010292-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.semarthrit.2008.12.003","article-title":"Prevalence of fibromyalgia: a survey in five European countries","volume":"39","author":"Branco","year":"2010","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD010292-BIB0028|cit28","first-page":"16","article-title":"Drugs to treat fibromyalgia - the transatlantic difference","volume":"11","author":"Briley","year":"2010","journal-title":"Current Opinion in Investigational Drugs"},{"key":"10.1002\/14651858.CD010292-BIB0029|cit29","volume-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988"},{"issue":"2","key":"10.1002\/14651858.CD010292-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"Journal of Pain"},{"issue":"3","key":"10.1002\/14651858.CD010292-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.pain.2009.08.019","article-title":"Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations","volume":"146","author":"Dworkin","year":"2009","journal-title":"Pain"},{"key":"10.1002\/14651858.CD010292-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010292-BIB0033|cit33","unstructured":"European Medicines Agency REFUSAL ASSESSMENT REPORT FOR Cymbalta International non-proprietary name\/Common name:(duloxetine hydrochloride)Procedure No. EMEA\/H\/C\/572\/II\/26 Available at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000572\/WC500076168.pdf"},{"key":"10.1002\/14651858.CD010292-BIB0034|cit34","unstructured":"European Medicines Agenccy REFUSAL ASSESSMENT REPORT FOR Milnacipran Pierre Fabre Medicament. International Non-proprietary Name: milnacipran. Procedure No. EMEA\/H\/C\/001034 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001034\/WC500089828.pdf"},{"key":"10.1002\/14651858.CD010292-BIB0035|cit35","unstructured":"FDA center for drug evaluation and research Approval duloxetine (Cymbalta) Available at www.fda.gov\/cder\/foi\/appletter\/2008\/022148s000ltr.pdf."},{"key":"10.1002\/14651858.CD010292-BIB0036|cit36","unstructured":"FDA center for drug evaluation and research Approval milnacipran (Savella) Available at www.fda.gov\/cder\/foi\/appletter\/2009\/022256ltr.pdf."},{"issue":"4","key":"10.1002\/14651858.CD010292-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00296-010-1713-x","article-title":"Individuals with fibromyalgia and depression: Findings from a nationally representative Canadian survey","volume":"32","author":"Fuller-Thomson","year":"2012","journal-title":"Rheumatology International"},{"key":"10.1002\/14651858.CD010292-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analyses","volume":"20","author":"Furukawa","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD010292-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal Clinical Epidemiology"},{"key":"10.1002\/14651858.CD010292-BIB0040|cit40","first-page":"1552","article-title":"Pain, disability, and pain\/disability relationships in seven rheumatic disorders: a study of 1,522 patients","volume":"18","author":"Hawley","year":"1991","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD010292-BIB0041|cit41","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD010292-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s00482-007-0602-z","article-title":"What are the key symptoms of fibromyalgia? Results of a survey of the German Fibromyalgia Association","volume":"22","author":"H\u00e4user","year":"2008","journal-title":"Schmerz"},{"issue":"23","key":"10.1002\/14651858.CD010292-BIB0043|cit43","first-page":"383","article-title":"Fibromyalgia syndrome: classification, diagnosis, and treatment","volume":"106","author":"H\u00e4user","year":"2009","journal-title":"Deutsches \u00c4rzteblatt international\u00a0"},{"issue":"8","key":"10.1002\/14651858.CD010292-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/acr.20328","article-title":"Emotional, physical and sexual abuse in fibromyalgia syndrome - a systematic review with meta-analysis","volume":"63","author":"H\u00e4user","year":"2011","journal-title":"Arthritis Care and Research"},{"issue":"6","key":"10.1002\/14651858.CD010292-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jpain.2010.01.002","article-title":"Comparative efficacy and harms of duloxetine, milnacipran and pregabalin in fibromyalgia syndrome","volume":"11","author":"H\u00e4user","year":"2010","journal-title":"Journal Pain"},{"issue":"3","key":"10.1002\/14651858.CD010292-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/ar3002","article-title":"Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials","volume":"12","author":"H\u00e4user","year":"2010","journal-title":"Arthritis Research Therapy"},{"key":"10.1002\/14651858.CD010292-BIB0047|cit47","doi-asserted-by":"crossref","unstructured":"H\u00e4user W Bartram-Wunn E Bartram C Reinecke H T\u00f6lle T Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors Pain 2011","DOI":"10.1016\/j.pain.2011.01.050"},{"issue":"3","key":"10.1002\/14651858.CD010292-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/rheumatology\/keq354","article-title":"Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis","volume":"50","author":"H\u00e4user","year":"2011","journal-title":"Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD010292-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"e37504","DOI":"10.1371\/journal.pone.0037504","article-title":"Validation of the Fibromyalgia Survey Questionnaire within a cross-sectional survey","volume":"7","author":"H\u00e4user","year":"2012","journal-title":"PLOS One"},{"issue":"9","key":"10.1002\/14651858.CD010292-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1345\/aph.1P218","article-title":"Milnacipran for treatment of fibromyalgia","volume":"44","author":"Kyle","year":"2010","journal-title":"Annals of Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD010292-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II","volume":"58","author":"Lawrence","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD010292-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Lee YH Choi SJ Ji JD Song GG Candidate gene studies of fibromyalgia: a systematic review and meta-analysis Rheumatology International 2010","DOI":"10.1007\/s00296-010-1678-9"},{"issue":"3","key":"10.1002\/14651858.CD010292-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/rheumatology\/40.3.290","article-title":"Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome","volume":"40","author":"Legangneux","year":"2001","journal-title":"Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD010292-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.3899\/jrheum.090367","article-title":"Fibromyalgia syndrome module at OMERACT 9: domain construct","volume":"36","author":"Mease","year":"2009","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD010292-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pain.2010.05.011","article-title":"\"Evidence\" in chronic pain--establishing best practice in the reporting of systematic reviews","volume":"150","author":"Andrew Moore","year":"2010","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD010292-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.pain.2010.02.039","article-title":"Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain","volume":"149","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD010292-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pain.2009.08.007","article-title":"Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences","volume":"149","author":"Moore","year":"2010","journal-title":"Pain"},{"key":"10.1002\/14651858.CD010292-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pain.2011.10.004","article-title":"Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses","volume":"153","author":"Moore","year":"2012","journal-title":"Pain"},{"issue":"4","key":"10.1002\/14651858.CD010292-BIB0059|cit59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006192","article-title":"Anti-depressants and centrally active agents for fibromyalgia syndrome","author":"Nishishinya","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD010292-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/00005650-200110000-00002","article-title":"Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life","volume":"39","author":"Norman","year":"2001","journal-title":"Medical Care"},{"key":"10.1002\/14651858.CD010292-BIB0061|cit61","first-page":"15","article-title":"Milnacipran for the management of fibromyalgia syndrome","volume":"3","author":"Ormseth","year":"2010","journal-title":"Journal of Pain Research"},{"issue":"4","key":"10.1002\/14651858.CD010292-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1086\/650004","article-title":"Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care","volume":"15","author":"Routman","year":"2010","journal-title":"Clinical Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD010292-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/art.1780350509","article-title":"Cerebrospinal fluid biogenic amine metabolites in fibromyalgia\/fibrositis syndrome and rheumatoid arthritis","volume":"35","author":"Russell","year":"1992","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD010292-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jbspin.2010.05.003","article-title":"Fibromyalgia syndrome: prevalence, pharmacological and non-pharmacological interventions in outpatient health care. An analysis of statutory health insurance data","volume":"78","author":"Sauer","year":"2011","journal-title":"Joint, Bone, Spine: Revue du Rhumatisme"},{"key":"10.1002\/14651858.CD010292-BIB0065|cit65","volume-title":"Fibrositis and other diffuse musculoskeletal syndromes. Textbook of Reumathology.","author":"Smythe","year":"1981"},{"issue":"3","key":"10.1002\/14651858.CD010292-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00482-012-1174-0","article-title":"Etiology and pathophysiology of fibromyalgia syndrome","volume":"26","author":"Sommer","year":"2012","journal-title":"Schmerz"},{"issue":"4","key":"10.1002\/14651858.CD010292-BIB0067|cit67","first-page":"391","article-title":"Efficacy and safety of duloxetine in fibromyalgia","volume":"161","author":"Ursini","year":"2010","journal-title":"Clinical Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD010292-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2165\/11535250-000000000-00000","article-title":"Impact of fibromyalgia severity on health economic costs: results from a European cross-sectional study","volume":"9","author":"Winkelmann","year":"2011","journal-title":"Applied Health Economics and Health Policy"},{"issue":"12","key":"10.1002\/14651858.CD010292-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/art.1780331217","article-title":"The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis and Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD010292-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/art.1780400904","article-title":"A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia","volume":"40","author":"Wolfe","year":"1997","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD010292-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.20140","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD010292-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pain.2010.09.027","article-title":"The development of fibromyalgia - I: examination of rates and predictors in patients with rheumatoid arthritis (RA)","volume":"152","author":"Wolfe","year":"2011","journal-title":"Pain"},{"issue":"6","key":"10.1002\/14651858.CD010292-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3899\/jrheum.100594","article-title":"Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia","volume":"38","author":"Wolfe","year":"2011","journal-title":"Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD010292-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0049-0172(81)90096-2","article-title":"Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls","volume":"11","author":"Yunus","year":"1981","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD010292-BIB0075|cit75","first-page":"115","article-title":"Primary fibromyalgia","volume":"25","author":"Yunus","year":"1982","journal-title":"American Family Physician"},{"issue":"8","key":"10.1002\/14651858.CD010292-BIB0076|cit76","first-page":"21","article-title":"Primary fibromyalgia syndrome: current concepts","volume":"10","author":"Yunus","year":"1984","journal-title":"Comprehensive Therapy"}],"updated-by":[{"DOI":"10.1002\/14651858.cd010292.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T00:00:00Z","timestamp":1519776000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010292","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:42:29Z","timestamp":1628534549000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD010292"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,31]]},"references-count":76,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010292","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717985597.793473192","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717985597.793473001","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,31]]}}}